FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine, particularly to experimental cardiopharmacology and can be used for endothelium dysfunction correction. For this purpose dysfunction is modelled by intraperitoneal introduction of L-nitro-arginine-methyl ester dosed 25 mg/kg daily during 7 days to rats. This therapy is combined with endogastric introduction of macrolide agent Josamycin dosed 10 and 30 mg/kg singly a day.
EFFECT: method provides correction in any antioxidant profile.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MIDECAMYCIN-BASED CORRECTION MODE OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2007 |
|
RU2353370C1 |
| METHOD FOR AZITHROMYCIN-BASED ENDOTHELIAL DYSFUNCTION CORRECTION IN EXPERIMENTAL REACTIVE VASCULITIS | 2009 |
|
RU2402333C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF INDAPAMIDE AND L-ARGININE IN L-NAME-INDUCED NITROGEN DEFICIT | 2005 |
|
RU2306929C1 |
| METHOD FOR COMBINED TADALAFIL AND L-NORVALINE CORRECTION OF L-NAME INDUCED NITROGEN OXIDE DEFICIENCY IN EXPERIMENT | 2012 |
|
RU2500040C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF ENALAPRIL AND RESVERATROL IN L-NAME-INDUCED DEFICIENCY OF NITROGEN OXIDE | 2005 |
|
RU2301670C1 |
| METHOD OF LAMOTRIGINE CORRECTION OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2008 |
|
RU2367421C1 |
| METHOD OF TADALAFIL-BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364395C1 |
| METHOD OF ENDOTHELIAL DYSFUNCTION CORRECTION BY COMBINATION OF HELIUM AND OXYGEN IN L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2012 |
|
RU2479873C1 |
| METHOD OF CORRECTION OF ENDOTHELIAL DYSFUNCTION BY PHOSPHOGLIV PREPARATION AT L-NAME INDUCED DEFICIENCY OF NITROGEN OXIDE | 2008 |
|
RU2359668C1 |
| METHOD OF ACETYLSALICYLIC ACID BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364392C1 |
